Saadoun Rakan, Bengur Fuat Baris, Moroni Elizabeth A, Surucu Yusuf, Veit Johannes A, Sadick Haneen, Smith Roy E, Kubik Mark, Sridharan Shaum, Solari Mario G
Department of Plastic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Ruprecht Karls University Heidelberg, Faculty of Medicine Mannheim, Mannheim, Germany.
Microsurgery. 2023 Oct;43(7):649-656. doi: 10.1002/micr.31029. Epub 2023 Feb 27.
Venous Thromboembolism (VTE) is a serious complication after free tissue transfer to the head and neck (H&N). However, an optimal antithrombotic prophylaxis protocol is not defined in the literature. Enoxaparin 30 mg twice daily (BID) and heparin 5000 IU three times daily (TID) are among the most commonly used regimens for chemoprophylaxis. However, no studies compare these two agents in the H&N population.
A cohort study of patients who underwent free tissue transfer to H&N from 2012 to 2021 and received either enoxaparin 30 mg BID or Heparin 5000 IU TID postoperatively. Postoperative VTE and hematoma events were recorded within 30 days of index surgery. The cohort was divided into two groups based on chemoprophylaxis. VTE and hematoma rates were compared between the groups.
Out of 895 patients, 737 met the inclusion criteria. The mean age and Caprini score were 60.6 [SD 12.5] years and 6.5 [SD 1.7], respectively. 234 [31.88%] were female. VTE and hematoma rates among all patients were 4.47% and 5.56%, respectively. The mean Caprini score between the enoxaparin (n = 664) and heparin (n = 73) groups was not statistically significant (6.5 ± 1.7 vs.6.3 ± 1.3, p = 0.457). The VTE rate in the enoxaparin group was significantly lower than in the heparin group (3.9% vs. 9.6%; OR: 2.602, 95% CI: 1.087-6.225). Hematoma rates were similar between the two groups (5.5% vs. 5.6%; OR: 0.982, 95% CI: 0.339-2.838).
Enoxaparin 30 mg BID was associated with a lower VTE rate while maintaining a similar hematoma rate compared to heparin 5000 units TID. This association may support the use of enoxaparin over heparin for VTE chemoprophylaxis in H&N reconstruction.
静脉血栓栓塞症(VTE)是头颈部(H&N)游离组织移植术后的一种严重并发症。然而,文献中尚未定义最佳的抗栓预防方案。依诺肝素30mg每日两次(BID)和肝素5000IU每日三次(TID)是最常用的化学预防方案。然而,尚无研究在H&N人群中比较这两种药物。
一项队列研究,研究对象为2012年至2021年接受H&N游离组织移植且术后接受依诺肝素30mg BID或肝素5000IU TID治疗的患者。在初次手术的30天内记录术后VTE和血肿事件。根据化学预防措施将队列分为两组。比较两组之间的VTE和血肿发生率。
895例患者中,737例符合纳入标准。平均年龄和Caprini评分分别为60.6[标准差12.5]岁和6.5[标准差1.7]。234例(31.88%)为女性。所有患者的VTE和血肿发生率分别为4.47%和5.56%。依诺肝素组(n = 664)和肝素组(n = 73)之间的平均Caprini评分无统计学差异(6.5±1.7对6.3±1.3,p = 0.457)。依诺肝素组的VTE发生率显著低于肝素组(3.9%对9.6%;OR:2.602,95%CI:1.087 - 6.225)。两组之间的血肿发生率相似(5.5%对5.6%;OR:0.982,95%CI:0.339 - 2.838)。
与肝素5000单位TID相比,依诺肝素30mg BID与较低的VTE发生率相关,同时血肿发生率相似。这种关联可能支持在H&N重建中使用依诺肝素而非肝素进行VTE化学预防。